#72
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand that modern cannabis products contain significantly higher THC concentrations than historical street marijuana, which may increase risks of acute psychiatric symptoms, cognitive impairment, and cannabis use disorder, particularly in adolescents whose brains are still developing. Patients and parents should receive evidence-based counseling about these potency changes when discussing cannabis use, as conventional risk information from past decades may underestimate current harms. Healthcare providers should screen for cannabis use patterns in teen and young adult patients and counsel against use during critical developmental windows when possible neurotoxic effects are greatest.
This article raises public health concerns about the changing potency and composition of modern cannabis products, particularly regarding their effects on adolescent neurodevelopment. Contemporary cannabis, especially concentrated forms like oils and edibles, typically contains significantly higher THC concentrations than historical cannabis, which may increase risks for cognitive impairment, psychiatric symptoms, and cannabis use disorder in young users whose brains are still developing. The advocacy perspective presented emphasizes that clinicians should be aware of these potency increases when counseling patients and families about cannabis risks, as the products available today differ substantially from those of previous decades. This distinction is particularly relevant for adolescent populations, where emerging evidence suggests greater vulnerability to adverse neuropsychiatric outcomes from high-potency products. Clinicians should incorporate information about modern cannabis potency into substance use screening and risk discussions with teenage patients and their parents, and consider referring high-risk youth to specialized addiction services when cannabis use is identified.
“What we’re seeing in my practice is that the potency increase is real and clinically significant, but the greater concern isn’t potency per se—it’s that adolescents are using products their brains aren’t equipped to process safely, and we’re doing this experiment without proper informed consent or medical supervision. We need to stop pretending this is equivalent to the cannabis of thirty years ago while also resisting the urge to demonize the plant itself.”
💭 While concerns about rising tetrahydrocannabinol (THC) potency in modern cannabis products are understandable, healthcare providers should recognize that Kevin Sabet’s advocacy organization has a clear policy agenda that may influence the framing of available evidence. The scientific literature does show associations between high-potency cannabis use and psychotic symptoms, particularly in adolescents whose brains are still developing, yet population-level data on cannabis-related harms have not uniformly escalated in proportion to reported potency increases, suggesting other factors—including frequency of use, route of administration, and individual vulnerability—substantially modify risk. When counseling patients and families, clinicians should acknowledge that adolescent cannabis use carries genuine neurobiological risks independent of potency, while avoiding overstated claims that cannot be fully substantiated by current epidemiologic data. A practical approach involves assessing individual risk factors (family history of psychosis, early use, heavy
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: